


World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2018 August 15; 10(8): 202-220





MINIREVIEWS

- 202 Shattering the castle walls: Anti-stromal therapy for pancreatic cancer
Kanat O, Ertas H

SYSTEMATIC REVIEWS

- 211 Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?
Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Xin-Zu Chen, MD, PhD, Associate Professor, Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

AIM AND SCOPE

World Journal of Gastrointestinal Oncology (World J Gastrointest Oncol, WJGO), online ISSN 1948-5204, DOI: 10.4251 is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGO covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ABSTRACTING

World Journal of Gastrointestinal Oncology (WJGO) is now indexed in Science Citation Index Expanded (also known as SciSearch[®]), PubMed, and PubMed Central. The 2018 edition of Journal Citation Reports[®] cites the 2017 impact factor for *WJGO* as 3.140 (5-year impact factor: 3.228), ranking *WJGO* as 39 among 80 journals in gastroenterology and hepatology (quartile in category Q2), and 114 among 222 journals in oncology (quartile in category Q3).

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*

Responsible Electronic Editor: *Wen-Wen Tan*

Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*

Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1948-5204/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director
World Journal of Gastrointestinal Oncology
Baishideng Publishing Group Inc

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-2238242

Fax: +1-925-2238243

E-mail: editorialoffice@wjgnet.com

Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc

7901 Stoneridge Drive,
Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-2238242

Fax: +1-925-2238243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE

August 15, 2018

COPYRIGHT

© 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION

<http://www.f6publishing.com>

Shattering the castle walls: Anti-stromal therapy for pancreatic cancer

Ozkan Kanat, Hulya Ertas

Ozkan Kanat, Hulya Ertas, Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa 16059, Turkey

ORCID number: Ozkan Kanat (0000-0001-6973-6540); Hulya Ertas (0000-0001-8306-4349).

Author contributions: Kanat O assigned the topic, wrote the manuscript, and generated the figure; Ertas H contributed to the collection of the relevant references and writing manuscript.

Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Faculty of Medicine, Uludag University, Gorukle, Bursa 16059, Turkey. ozkanat@uludag.edu.tr
Telephone: +90-224-2951321

Received: March 30, 2018

Peer-review started: March 30, 2018

First decision: April 23, 2018

Revised: June 19, 2018

Accepted: June 27, 2018

Article in press: June 27, 2018

Published online: August 15, 2018

Abstract

Despite the availability of potent chemotherapy regimens, such as 5-fluorouracil, folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX) and nab-paclitaxel plus gemcitabine, treatment outcomes in metastatic pancreatic cancer

(PC) remain unsatisfactory. The presence of an abundant fibrous stroma in PC is considered a crucial factor for its unfavorable condition. Apparently, stroma acts as a physical barrier to restrict intratumoral cytotoxic drug penetration and creates a hypoxic environment that reduces the efficacy of radiotherapy. In addition, stroma plays a vital supportive role in the development and progression of PC, which has prompted researchers to assess the potential benefits of agents targeting several cellular (e.g., stellate cells) and acellular (e.g., hyaluronan) elements of the stroma. This study aims to briefly review the primary structural properties of PC stroma and its interaction with cancer cells and summarize the current status of anti-stromal therapies in the management of metastatic PC.

Key words: Pancreatic cancer; Stroma; Stellate cells; Hyaluronan; Secreted protein acidic and rich in cysteine

© **The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The primary characteristic of pancreatic adenocarcinoma is the presence of an extensive desmoplastic stroma around neoplastic cells. In this study, we aim to briefly review the primary structural properties of pancreatic cancer (PC) stroma and its interaction with cancer cells and summarize the current status of anti-stromal therapies in the management of metastatic PC.

Kanat O, Ertas H. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. *World J Gastrointest Oncol* 2018; 10(8): 202-210 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v10/i8/202.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v10.i8.202>

INTRODUCTION

The primary characteristic of pancreatic adenocarcinoma is the presence of an extensive desmoplastic stroma

around neoplastic cells in both primary and metastatic lesions^[1]. The structural organization of stroma is not entirely different from those in other solid tumors; in fact, it is a mixture of cellular and acellular [extracellular matrix (ECM) proteins] elements^[2]. However, in contrast to several other solid tumors, stromal elements can occupy $\geq 80\%$ of the total tumor volume in most pancreatic cancer (PC) cases^[3].

Abundant accumulation of fibrous proteins, primarily collagen (types I and III), fibronectin, and secreted protein acidic and rich in cysteine (SPARC) in the ECM offers exceptional mechanical properties of pancreatic adenocarcinoma stroma, including considerably enhanced stiffness and reduced elasticity^[4]. In addition, increased deposition of another crucial ECM element hyaluronan (HA) in the tumor stroma creates substantial swelling stress, which progressively increases the interstitial fluid pressure^[5]. The occurrence of this condition besides increased tissue stiffness compresses intratumoral blood vessels, resulting in tumor hypoperfusion and hypoxia. Reportedly, hypoperfusion drastically reduces intratumoral delivery of chemotherapy drugs and, consequently, their efficacy^[6,7]. Hypoxia confers a survival advantage for neoplastic cells and potentiates their invasion, stemness, and metastatic capacity primarily through the hypoxia-inducible factor-1 α -mediated hepatocyte growth factor/c-Met pathway activation^[8,9]. Moreover, hypoxia compromises the efficacy of radiotherapy.

In PC, ECM proteins are primarily produced by a distinct type of stromal cells called activated pancreatic stellate cells (PSCs). PSCs phenotypically resemble myofibroblasts and exhibit the α -smooth muscle actin expression. However, in contrast to myofibroblasts, PSCs are positively stained for selective markers such as desmin and glial fibrillary acidic protein. They also demonstrate increased proliferation and migration ability relative to myofibroblasts, and can produce large amounts of collagen and other ECM proteins^[10,11]. PSCs possess the adequate capacity to interact with cancer cells and other stromal cells (*i.e.*, immune cells, inflammatory cells, and endothelial cells) to extend stroma and promote cancer progression. Thus, both cellular (especially PSCs) and acellular (especially HA) components of PC stroma have been held accountable for unsatisfactory treatment outcomes in patients with PC. This condition has encouraged PC researchers to elucidate the potential beneficial effects of stroma disrupting agents alone or in combination with standard chemotherapy in the treatment of PC (Figure 1).

ROLES OF PSCS IN PC PROGRESSION

Despite being debatable, activated PSCs are deliberated to originate from their inactive (quiescent) forms that are primarily found in the periacinar space of the exocrine pancreas^[12]. Reportedly, inflammatory (*i.e.*, interleukin-1 and interleukin-6, and tumor necrosis factor- α) and

mitogenic (*i.e.*, transforming growth factor and platelet-derived growth factor) cytokines secreted by cancer cells are accountable for the PSC activation^[13-18]. Perhaps, some intracellular pathways, including p38 mitogen-activated protein kinase, RhoA/Rho kinase, and cyclooxygenase-2, could play a vital role in this process^[18-22].

In pancreatic carcinogenesis, activated PSCs seemingly serve two primary functions, to produce ECM molecules and regulate the formation of desmoplastic reaction and enable cancer cell proliferation and invasion^[13]. The direct cell-to-cell contact between PSCs and PC cells has been demonstrated to result in the activation of the Notch signaling pathway in both cell types^[23]. The Notch signaling plays a vital role in the proliferation, migration, differentiation, and apoptosis of cancer cells^[24,25]. Apparently, PSCs can activate the mitogen-activated protein kinase and Akt pathways in tumor cells, causing enhanced tumor growth and metastasis^[26]. PSCs secrete matrix metalloproteinase-2 into the tumor microenvironment in response to extracellular matrix metalloproteinase inducer (EMMPRIN) secreted by cancer cells to facilitate the tissue invasion and metastasis^[27]. In addition, PSCs can accompany cancer cells to distant sites, where they stimulate angiogenesis, cancer cell seeding, survival, and proliferation and, thus, facilitate the metastasis formation^[28]. Furthermore, PSCs can indirectly protect cancer cells from the immune system attack. A study demonstrated that PSCs secreted CXCL12 chemokine and sequestered CD8⁺ T cells to reduce their accumulation in the juxtatumoral compartments^[29]. Mace *et al.*^[30] suggested that PSC-derived cytokines, such as interleukin-6, cause myeloid-derived suppressor cell expansion in the stroma, thereby indirectly inducing immune cell dysfunction.

Preclinical data indicated that PSCs might enhance stem-cell like phenotypes in PC cells^[31]. Indirect co-culture of PSCs with PC cells increased the spheroid-forming capacity of tumor cells, and induced the expression of stem cell-related genes including Nestin, ABCG2 and LIN28^[31]. Lonardo *et al.*^[32] showed that the secretion of transforming growth factor- β superfamily members Nodal and Activin from PSCs significantly promotes the self-renewal capacity and invasiveness of PC stem cells.

Recent studies have shown that extracellular vesicles (also known as exosomes) derived from PSCs may play a role in the progression of PC^[33,34]. Takikawa *et al.*^[34] reported that immortalized human PSCs produce exosomes containing numerous microRNAs (miRNAs) that can induce chemokine gene expression in PC cell lines resulted in increased proliferation and migration. Leca *et al.*^[35] found that annexin 6A/receptor-related protein 1/thrombospondin-1 complex-containing exosomes released by PSCs could increase PC cell aggressiveness under physiopathologic conditions. In addition, exosomes have been suggested to contribute to chemoresistance of PC cells by promoting reactive oxygen species detoxification and by decreasing gemcitabine-metabolizing enzyme activity^[36].




Figure 1 Stroma-targeting treatment strategies in pancreatic cancer. SPARC: Secreted protein acidic and rich in cysteine.

POTENTIAL THERAPEUTIC STRATEGIES TARGETING PSCS

Vitamin D and A analogs

Preclinical studies have reported that the PSC activation can be restricted or reversed by pharmacological interventions leading to substantial modulation of the tumor stroma^[37,38]. Apparently, PSCs express higher levels of vitamin D receptors^[37]. Sherman *et al.*^[37] reported that a potent vitamin D analog calcipotriol treatment decreased the expression of activation and cancer signature genes in cultured PSCs, stimulated lipid droplet formation, and reduced the α -smooth muscle actin expression, signifying their inactivation; this correlated with a decline in stromal inflammation and fibrosis. In addition, the authors compared the efficacy of gemcitabine plus calcipotriol treatment with gemcitabine alone in the KPC model of PC and reported that the combination therapy increased the intratumoral uptake of gemcitabine, reduced tumor volume, and exhibited 57% improvement in animal survival compared with gemcitabine monotherapy. These findings suggested that the tumor stromal modulation (reprogramming) by inactivating PSCs could be a reasonable treatment strategy for PC. Paricalcitol, a synthetic vitamin D analog is currently being tested in combination with conventional chemotherapy or immunotherapy in the treatment of metastatic PC (Table 1).

Quiescent PSCs store vitamin A-containing lipid droplets in their cytoplasm, which are lost during the activation process. Research has revealed that restoring vitamin A in PSCs by using vitamin A metabolites could reprogram these cells to a quiescent phase^[39]. Jaster *et al.*^[40] reported that all-trans-retinoic acid (ATRA) could impede the proliferation and collagen synthesis of PSCs isolated from rat pancreas by hindering the AP-1 activation. Of note, AP-1 is a transcription factor that regulates cell growth, differentiation, and survival. McCarroll *et al.*^[41] described that ATRA and 9-cis retinoic acid could avert the activation of cultured activated PSCs by inhibiting the mitogen-activated protein kinase signaling pathway, and

decreased collagen I, fibronectin, and laminin expression in these cells. In addition, a study reported that the reduction of Wnt-B-catenin signaling by ATRA in PC cells resulted in slower tumor progression^[42]. Furthermore, Chronopoulos *et al.*^[43] determined that ATRA could reduce the actomyosin-dependent contractility, mechanosensing, and migration of PSCs in a retinoic acid receptor (RAR)- β -dependent manner. Likewise, Sarper *et al.*^[39] also reported similar findings. Overall, reprogramming of PSCs using vitamin A metabolites, such as ATRA or selective RAR- β agonists, in a clinical setting could open new avenues in the treatment of PC (Table 1).

Antifibrotic agents

Kozono *et al.*^[44] reported that the antifibrotic anti-inflammatory agent pirfenidone could impede the proliferation, invasiveness, migration, and ECM protein synthesis ability of PSCs in vitro. In mice bearing orthotopically implanted PC and PSCs, pirfenidone was shown to suppress the tumor growth and metastasis formation and displayed a synergistic antitumor effect with gemcitabine. In addition, Suklabaidya *et al.*^[45] reported that the effects of pirfenidone could be potentiated when co-administered with antioxidant N-acetyl cysteine. Thus, the potential effects of pirfenidone alone or in combination with N-acetyl cysteine in PC necessitate further assessment in human subjects.

Angiotensin II inhibitors

Previously, preclinical studies have demonstrated that angiotensin II plays a promoting role in the PSC proliferation, which seems to be controlled by induction of the Smad7 expression through a protein kinase C-dependent pathway, resulting in the inhibition of TGF- β 1 signaling^[46]. On the basis of these findings, several angiotensin II receptor antagonists have been investigated as a potential strategy to reduce PSC-mediated stromal fibrosis. Yamada *et al.*^[47] reported that candesartan considerably reduces the PSC proliferation and decreases the histological score of experimental

Table 1 Summary of existing studies evaluating the efficacy of anti-stromal agents in the treatment of metastatic pancreatic cancer

Agent	Target	Treatment arm (s)	Type of study	National clinical trial number	Status	Results
Paricalcitol	Vitamin D metabolic pathway	Gemcitabine and nab-paclitaxel plus paricalcitol or placebo	Phase I / II	NCT03520790	Recruiting	
		Nab-paclitaxel, cisplatin and gemcitabine plus paricalcitol	Phase II	NCT03415854	Recruiting	
		Nivolumab ¹ , nab-paclitaxel, cisplatin, and gemcitabine plus paricalcitol	Phase II	NCT02754726	Recruiting	
		Pembrolizumab ¹ plus paricalcitol or placebo	Phase II	NCT03331562	Recruiting	
All trans retinoic acid	Pancreatic stellate cells	Gemcitabine and nab-paclitaxel plus all trans retinoic acid	Phase I	NCT03307148	Recruiting	
Vismodegib	Hedgehog signaling	Gemcitabine plus vismodegib or placebo	Phase I / II	NCT0106422	Completed	Vismodegib did not improve ORR, PFS and OS
IPI-926	Hedgehog signaling	FOLFIRINOX plus IPI-926	Phase I	NCT01383538	Completed	The combination treatment was safe but IP-926 was not beneficial
		Gemcitabine plus IPI-926 or placebo	Phase I / II	NCT01130142	Completed	The combination treatment was well tolerated, and showed promising activity
PEGPH20	Hyaluronic acid	Gemcitabine and nab-paclitaxel plus PEGPH20 <i>vs</i> chemotherapy alone	Phase II	NCT01839487	Completed	PEGPH20 significantly improved PFS, especially in patients having tumors with high-level hyaluronic acid
		Gemcitabine and nab-paclitaxel plus PEGPH20 or placebo ²	Phase III	NCT02715804	Recruiting	
		Modified FOLFIRINOX plus PEGPH20 <i>vs</i> chemotherapy alone	Phase I / II	NCT01959139	Closed	PEGPH20 was found to have a detrimental effect on OS

¹Nivolumab and Pembrolizumab: PD-1-targeted T-cell checkpoint inhibitors; ²This study included only patients whose tumors had high levels of hyaluronic acid. ORR: Overall response rate; PFS: Progression-free survival; OS: Overall survival; FOLFIRINOX: 5-fluorouracil, irinotecan and, oxaliplatin.

pancreatic inflammation and fibrosis formation by avoiding the activation of TGF- β 1 signaling. In addition, Masamune *et al*^[48] investigated the effects of another angiotensin II antagonist, olmesartan, on PC-associated fibrosis in a subcutaneous xenograft model. Apparently, olmesartan could inhibit the PSC proliferation and collagen I production, resulting in the tumor growth suppression. Nevertheless, further preclinical data are warranted before advancing these agents to clinical trials.

Upregulation of microRNAs in PSCs

miRNAs are small noncoding RNA molecules involved in RNA silencing and post-transcriptional gene expression regulation. A study reported that miR-21, a profibrotic miRNA, is upregulated in cancer-associated myofibroblasts and PSCs isolated from resected PC tissues^[49]. In addition, PC cells have been assumed to induce miR-21 upregulation in these cells, expediting their invasion and metastasis^[49]. Donahue *et al*^[50] reported that a high stromal miR-21 level correlated with worse overall survival in patients with PC who received adjuvant 5-fluorouracil but not gemcitabine. A meta-analysis showed that miR-21 upregulation in tumor tissue and blood samples of patients with PC was significantly associated with poorer overall survival, disease-free survival, and progression-free survival. A significant correlation was detected between miR-21 expression and lymph node status and tumor grade^[51]. Frampton *et al*^[52] reported that, in addition to miR-21, other miRNAs, such as miR-10b, miR-34, miR-155, and

miR-203 also appear to have prognostic significance in pancreatic ductal adenocarcinoma. The dysregulation of miR-320a, miR-365, miR-200, and miR-210 has been found to be involved in tumor invasion, epithelial to mesenchymal transition development, and chemotherapeutic drug resistance in PC^[53]. Thus, silencing of specific miRNAs by chemically modified antisense oligonucleotides could be a novel therapeutic intervention for PC.

Inhibition of hedgehog signaling in PSCs

Bailey *et al*^[54] were the first to report that sonic hedgehog (Hh) ligands secreted by PC can activate the canonical Hh signaling pathway in PSCs, resulting in their activation, differentiation, and proliferation. In addition, sonic Hh has been shown to promote desmoplasia in orthotopic mouse models of PC, and inhibiting sonic Hh with monoclonal antibody 5E1 markedly decreased the degree of desmoplasia^[54].

In their groundbreaking preclinical study, Olive *et al*^[55] assessed the effects of orally administered smoothed antagonist IPI-926 (or saridegib, a derivative of Hh inhibitor cyclopamine) on the tumor stroma and intratumoral uptake of gemcitabine in pancreatic tumor-bearing KPC mice. The result revealed that IPI-926 treatment considerably reduced the proliferation of stromal myofibroblasts, considerably depleted stromal components, and resulted in a transient increase in the intratumoral vascular density and intratumoral concentration of gemcitabine, facilitating transient disease stabilization. On the basis, in part, of

these findings, a phase I/III clinical study was commenced to assess the safety and efficacy of IPI-926 and gemcitabine combination treatment in metastatic PC^[56] (Table 1). The initial outcomes revealed that this combination was well tolerated and resulted in a partial response in 5 of 16 patients in the phase 1b portion of the study.

In another phase I study, IPI-926 was used in combination with 5-fluorouracil, folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX), a potent and intensive chemotherapy regimen, in the first-line treatment of advanced PC^[57]. The preliminary outcomes revealed that the unsubstantiated overall response rate was 66.7%, and that treatment-related toxicities were acceptable and tolerable. However, the initial findings of a phase I b/II study conducted by Catenacci *et al.*^[58] questioned the efficacy of Hh inhibition in advanced PC. The authors evaluated the synergistic activity of vismodegib, a small-molecule inhibitor of smoothened, and gemcitabine in patients with metastatic PC. They observed no safety concerns in the phase 1b portion of the study. In the phase II portion of the study, they randomized 106 patients into gemcitabine plus vismodegib or gemcitabine plus placebo groups, but observed no significant differences in the progression-free ($P = 0.30$) and overall survival ($P = 0.84$) between the two treatment groups. Moreover, the response rates were not significantly different (Table 1).

OTHER TARGETABLE ELEMENTS OF STROMA

Hyaluronan

Reportedly, the PC stroma might comprise a considerable amount of HA, which is a high-molecule glycosaminoglycan comprising repeating units of D-glucuronic acid and N-acetyl-glucosamine^[59,60]. Reportedly, HA levels in PC tissue might reach 12-fold higher than that found in healthy pancreatic tissue^[61]. In addition, PC cells typically express high levels of the primary HA receptor, CD44^[62,63]. When HA binds to CD44, four major signaling pathways activated in PC cells are as follows: RAS, Rac, MAPK, and phosphatidylinositol-3-kinase. In fact, signaling through these pathways accelerates the proliferation, epithelial-to-mesenchymal transition, stemness, and metastatic capacity of PC cells and increases their resistance against chemotherapeutic drugs^[64-70]. Besides its significant tumor-promoting effects, HA is a crucial contributor to the impaired blood perfusion of tumor cells, increased tumor hypoxia, and, more crucially, insufficient drug delivery to the tumor, as mentioned previously^[1,60,69,70].

Some preclinical studies have reported that the enzymatic degradation of HA using PEGylated human recombinant hyaluronidase PH20 (PEGPH20) in genetically engineered mouse models of PC could prompt the re-expansion of collapsed tumor vessels and promote doxorubicin and gemcitabine delivery. Furthermore, the combined use of gemcitabine and PEGPH20 exhibited a synergistic effect and substantially inhibited the tumor

growth, resulting in the upgraded survival of animals. Conversely, gemcitabine monotherapy only modestly affected the tumor growth compared with PEGPH20 alone^[60]. Provenzano *et al.*^[71] reported similar findings and observed that PEGPH20 effectively ablated HA from metastatic deposits as with primary tumors and reinstated the vascular pattern.

Consequently, a phase 1b study by Hingorani *et al.*^[72] evaluated the safety and efficacy of escalating doses of intravenous PEGPH20 combined with gemcitabine in patients with metastatic PC. The treatment was well tolerated by patients ($n = 28$) and exhibited a promising clinical activity. However, patients with tumors comprising higher HA levels seemingly benefited more from this treatment than those whose tumors had lower HA levels. In addition, the median progression-free and overall survival durations were 7.2 and 13 mo for patients with high HA levels and 3.5 and 5.7 mo for patients with low HA levels, respectively. Notably, these results encouraged further clinical research.

The final outcomes of phase 2 HALO-109-202 study, in which PEGPH20 was administered together with nab-paclitaxel plus gemcitabine regimen, were presented at the 2017 American Society of Clinical Oncology Annual Meeting^[73]. The study randomized 279 patients with untreated metastatic PC to receive either PEGPH20 plus chemotherapy (100 patients treated) or chemotherapy alone (160 patients treated). The combination therapy substantially improved the median progression-free survival (primary endpoint: 6.0 mo vs 5.3 mo; $P = 0.045$) in unselected patients. In HA-high patients (34% of enrolled patients), a significant increase was again noted in the progression-free survival with PEGPH20 plus chemotherapy compared with chemotherapy alone (median: 9.2 mo vs 5.2 mo; $P = 0.48$). However, no significant difference was observed between the two treatment arms regarding the overall survival (median: 11.5 mo vs 8.5 mo; HR, 0.96). Apparently, thromboembolic events pose a primary complication of PEGPH20 treatment. In the first stage of this phase 2 study, none of the patients randomized to PEGPH20 arm was provided thromboprophylaxis, and 43% of these developed thrombosis, causing a temporary cessation in the treatment. However, in the second stage, the rate of this complication was decreased to 28% with the administration of enoxaparin prophylaxis. PEGPH20 treatment was also associated with increased incidence and severity of other manageable side effects, such as painful muscle spasms, arthralgia, peripheral edema, and neutropenia. Overall, PEGPH20 is the first stroma-targeting agent that has demonstrated its efficacy in a clinical setting. Currently, a phase III study (HALO Pancreatic 301; NCT02715804) is recruiting patients with stage IV PC whose tumors have a high level of HA to validate phase II results.

In contrast, a recently presented randomized phase I/II study evaluating the efficacy of PEGPH20 and modified FOLFIRINOX in patients with metastatic PC who have a good performance status suggested that PEGPH20 can

have a detrimental effect on OS (HR = 0.48). Therefore, further studies are needed to clarify whether the benefit from the use of PEGPH20 is restricted to patients treated with gemcitabine and nab-paclitaxel^[74].

Secreted protein acidic and rich in cysteine

SPARC (also known as osteonectin or basement membrane protein 40) is a member of the matricellular proteins group and plays regulatory roles in cellular proliferation and adhesion. Guweidhi *et al.*^[75] described that primary and metastatic lesions of PC expressed SPARC 31-fold more compared with normal pancreatic tissue. In addition, PC cells fail to produce SPARC because of aberrant hypermethylation in their *SPARC* gene. Thus, almost all SPARC in PC tissue is produced by PSCs^[75-78]. Reportedly, SPARC can increase the migration ability and invasive properties of PC cells^[78-80]. In addition, SPARC can stimulate the MMP production in neoplastic cells, thereby enhancing their metastatic potential^[75,77,81,82]. Accordingly, patients with PC whose tumors contain elevated amounts of SPARC have been reported to have worse survival compared with those whose tumors contain lower SPARC levels following radical surgery or chemoradiotherapy^[80,83-85].

Owing to its high affinity for albumin, stromal SPARC, perhaps, increases the intratumoral delivery and efficacy of the chemotherapeutic drug albumin-bound paclitaxel (nab-paclitaxel) in patients with PC^[86]. In their phase I/II study, Von Hoff *et al.*^[86] examined the efficacy of escalating doses of nab-paclitaxel in combination with fixed doses gemcitabine in 67 patients with previously untreated metastatic PC. The treatment resulted in an overall response rate of 48%, and the median overall survival duration of 12.2 mo. In the study, the SPARC status was assessed in 36 patients, and patients whose tumors had high SPARC expression ($n = 19$) exhibited better overall survival than patients whose tumors displayed low SPARC expression (median: 17.8 mo vs 8.1 mo; $P = 0.0431$). In addition, the study established a significant correlation between the stromal SPARC level and the patients' survival ($P = 0.013$). However, SPARC in tumor cells did not exert any effect on survival ($P = 0.15$). Besides, the authors assessed the treatment-related stromal changes and intratumoral penetration of the drugs in a patient-derived xenograft mouse model of PC and demonstrated that tumors resected from mice treated with gemcitabine alone demonstrated an extensive desmoplastic stroma. However, tumors in mice treated with nab-paclitaxel alone or in combination with gemcitabine exhibited the reduced stromal content, which was accompanied by dilated tumor blood vessels. Thus, the intratumoral concentration of gemcitabine was determined to be 2.8-fold higher in nab-paclitaxel plus gemcitabine-treated mice compared with mice receiving gemcitabine alone.

On the basis of these results, Von Hoff *et al.*^[87] conducted a phase III study in which 861 patients with metastatic PC were randomly allotted to receive either nab-paclitaxel

plus gemcitabine or gemcitabine alone. Their findings established the superiority of the combination regimen over gemcitabine monotherapy. In addition, patients receiving nab-paclitaxel plus gemcitabine exhibited longer median overall survival compared with those receiving gemcitabine alone (8.5 mo vs 6.7 mo; $P < 0.001$). Furthermore, they demonstrated a better response rate (23% vs 7%; $P < 0.001$). Hence, it could be speculated that the tumor SPARC level could be used as a predictive marker to determine patients with advanced PC most likely to benefit from nab-paclitaxel-based chemotherapy.

CONCLUSION

Despite the determination of active chemotherapeutic regimens, such as nab-paclitaxel plus gemcitabine and FOLFIRINOX, in metastatic PC, the overall treatment outcomes remain inadequate. Perhaps, stroma-depletion strategies could provide novel treatment opportunities for patients with this formidable disease. Among them, the enzymatic degradation of stromal HA by PEGPH20 is currently the only effective method in the clinical setting. After the announcement of the final outcomes of the phase III HALO Pancreatic 301 study, PEGPH20 could be incorporated into standard-of-care treatment regimens in metastatic PC. Of note, promising preclinical effects of Hh inhibitors await clinical confirmation; however, these could exhibit a stronger activity and synergy when they are combined with potent chemotherapy combinations rather than gemcitabine monotherapy. Moreover, agents that have demonstrated promising anti-stromal activity in preclinical models, especially vitamin A and D analogs, warrant clinical testing and could extend the therapeutic armamentarium in the future.

REFERENCES

- 1 **Whatcott CJ**, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, Hostetter G, Shepard HM, Von Hoff DD, Han H. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. *Clin Cancer Res* 2015; **21**: 3561-3568 [PMID: 25695692 DOI: 10.1158/1078-0432.CCR-14-1051]
- 2 **Bahrami A**, Khazaei M, Bagherieh F, Ghayour-Mobarhan M, Maftouh M, Hassanian SM, Avan A. Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies. *J Cell Physiol* 2017; **232**: 2931-2937 [PMID: 28083912 DOI: 10.1002/jcp.25798]
- 3 **Neesse A**, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer. *Gut* 2011; **60**: 861-868 [PMID: 20966025 DOI: 10.1136/gut.2010.226092]
- 4 **Kota J**, Hancock J, Kwon J, Korc M. Pancreatic cancer: Stroma and its current and emerging targeted therapies. *Cancer Lett* 2017; **391**: 38-49 [PMID: 28093284 DOI: 10.1016/j.canlet.2016.12.035]
- 5 **Voutouri C**, Polydorou C, Papageorgis P, Gkretsi V, Stylianopoulos T. Hyaluronan-Derived Swelling of Solid Tumors, the Contribution of Collagen and Cancer Cells, and Implications for Cancer Therapy. *Neoplasia* 2016; **18**: 732-741 [PMID: 27886639 DOI: 10.1016/j.neo.2016.10.001]
- 6 **Stylianopoulos T**, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, Smith BL, Ferrone CR, Hornicek FJ, Boucher Y, Munn LL, Jain RK. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. *Proc Natl Acad*

- Sci USA* 2012; **109**: 15101-15108 [PMID: 22932871 DOI: 10.1073/pnas.1213353109]
- 7 **Jain RK**. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. *J Clin Oncol* 2013; **31**: 2205-2218 [PMID: 23669226 DOI: 10.1200/JCO.2012.46.3653]
 - 8 **Ide T**, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Miyazaki K. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. *Ann Surg Oncol* 2007; **14**: 2600-2607 [PMID: 17534684 DOI: 10.1245/s10434-007-9435-3]
 - 9 **Kitajima Y**, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. *Cancer Sci* 2008; **99**: 1341-1347 [PMID: 18422749 DOI: 10.1111/j.1349-7006.2008.00828.x]
 - 10 **Masamune A**, Shimosegawa T. Pancreatic stellate cells--multi-functional cells in the pancreas. *Pancreatology* 2013; **13**: 102-105 [PMID: 23561965 DOI: 10.1016/j.pan.2012.12.058]
 - 11 **Habisch H**, Zhou S, Siech M, Bachem MG. Interaction of stellate cells with pancreatic carcinoma cells. *Cancers (Basel)* 2010; **2**: 1661-1682 [PMID: 24281180 DOI: 10.3390/cancers2031661]
 - 12 **Bynigeri RR**, Jakkampudi A, Jangala R, Subramanyam C, Sasikala M, Rao GV, Reddy DN, Talukdar R. Pancreatic stellate cell: Pandora's box for pancreatic disease biology. *World J Gastroenterol* 2017; **23**: 382-405 [PMID: 28210075 DOI: 10.3748/wjg.v23.i3.382]
 - 13 **Vonlaufen A**, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, Toi CS, Pirola RC, Wilson JS, Goldstein D, Apte MV. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. *Cancer Res* 2008; **68**: 2085-2093 [PMID: 18381413 DOI: 10.1158/0008-5472.CAN-07-2477]
 - 14 **Apte MV**, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, Ramm GA, Buchler M, Friess H, McCarroll JA, Keogh G, Merrett N, Pirola R, Wilson JS. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. *Pancreas* 2004; **29**: 179-187 [PMID: 15367883 DOI: 10.1097/00006676-200410000-00002]
 - 15 **Bachem MG**, Schünemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A, Adler G. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. *Gastroenterology* 2005; **128**: 907-921 [PMID: 15825074 DOI: 10.1053/j.gastro.2004.12.036]
 - 16 **Dunér S**, Lopatko Lindman J, Ansari D, Gundewar C, Andersson R. Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. *Pancreatology* 2010; **10**: 673-681 [PMID: 21242706 DOI: 10.1159/000320711]
 - 17 **Bachem MG**, Zhou S, Buck K, Schneiderhan W, Siech M. Pancreatic stellate cells--role in pancreas cancer. *Langenbecks Arch Surg* 2008; **393**: 891-900 [PMID: 18204855 DOI: 10.1007/s00423-008-0279-5]
 - 18 **Jaster R**. Molecular regulation of pancreatic stellate cell function. *Mol Cancer* 2004; **3**: 26 [PMID: 15469605 DOI: 10.1186/1476-4598-3-26]
 - 19 **Apte MV**, Haber PS, Darby SJ, Rodgers SC, McCaughan GW, Korsten MA, Pirola RC, Wilson JS. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. *Gut* 1999; **44**: 534-541 [PMID: 10075961 DOI: 10.1136/gut.44.4.534]
 - 20 **Masamune A**, Shimosegawa T. Signal transduction in pancreatic stellate cells. *J Gastroenterol* 2009; **44**: 249-260 [PMID: 19271115 DOI: 10.1007/s00535-009-0013-2]
 - 21 **Erkan M**, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 454-467 [PMID: 22710569 DOI: 10.1038/nrgastro.2012.115]
 - 22 **Yoshida S**, Ujiki M, Ding XZ, Pelham C, Talamonti MS, Bell RH Jr, Denham W, Adrian TE. Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. *Mol Cancer* 2005; **4**: 27 [PMID: 16083499 DOI: 10.1186/1476-4598-4-27]
 - 23 **Fujita H**, Ohuchida K, Mizumoto K, Egami T, Miyoshi K, Moriyama T, Cui L, Yu J, Zhao M, Manabe T, Tanaka M. Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells. *Cancer Sci* 2009; **100**: 2309-2317 [PMID: 19735487 DOI: 10.1111/j.1349-7006.2009.01317.x]
 - 24 **Dang TP**. Notch, apoptosis and cancer. *Adv Exp Med Biol* 2012; **727**: 199-209 [PMID: 22399349 DOI: 10.1007/978-1-4614-0899-4_15]
 - 25 **Yuan X**, Wu H, Xu H, Xiong H, Chu Q, Yu S, Wu GS, Wu K. Notch signaling: an emerging therapeutic target for cancer treatment. *Cancer Lett* 2015; **369**: 20-27 [PMID: 26341688 DOI: 10.1016/j.canlet.2015.07.048]
 - 26 **Hwang RF**, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. *Cancer Res* 2008; **68**: 918-926 [PMID: 18245495 DOI: 10.1158/0008-5472.CAN-07-5714]
 - 27 **Zhang W**, Erkan M, Abiatari I, Giese NA, Felix K, Kaye H, Büchler MW, Friess H, Kleeff J. Expression of extracellular matrix metalloproteinase inducer (EMMPRN/CD147) in pancreatic neoplasm and pancreatic stellate cells. *Cancer Biol Ther* 2007; **6**: 218-227 [PMID: 17224648 DOI: 10.4161/cbt.6.2.3623]
 - 28 **Xu Z**, Vonlaufen A, Phillips PA, Fiala-Beer E, Zhang X, Yang L, Biankin AV, Goldstein D, Pirola RC, Wilson JS, Apte MV. Role of pancreatic stellate cells in pancreatic cancer metastasis. *Am J Pathol* 2010; **177**: 2585-2596 [PMID: 20934972 DOI: 10.2353/ajpath.2010.090899]
 - 29 **Ene-Obong A**, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J, Chelala C, Gribben JG, Ramsay AG, Kocher HM. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. *Gastroenterology* 2013; **145**: 1121-1132 [PMID: 23891972 DOI: 10.1053/j.gastro.2013.07.025]
 - 30 **Mace TA**, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GB. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. *Cancer Res* 2013; **73**: 3007-3018 [PMID: 23514705 DOI: 10.1158/0008-5472.CAN-12-4601]
 - 31 **Hamada S**, Masamune A, Takikawa T, Suzuki N, Kikuta K, Hirota M, Hamada H, Kobune M, Satoh K, Shimosegawa T. Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. *Biochem Biophys Res Commun* 2012; **421**: 349-354 [PMID: 22510406 DOI: 10.1016/j.bbrc.2012.04.014]
 - 32 **Lonardo E**, Frias-Aldeguer J, Hermann PC, Heeschen C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. *Cell Cycle* 2012; **11**: 1282-1290 [PMID: 22421149 DOI: 10.4161/cc.19679]
 - 33 **Qiu J**, Yang G, Feng M, Zheng S, Cao Z, You L, Zheng L, Zhang T, Zhao Y. Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. *Mol Cancer* 2018; **17**: 2 [PMID: 29304816 DOI: 10.1186/s12943-017-0755-z]
 - 34 **Takikawa T**, Masamune A, Yoshida N, Hamada S, Kogure T, Shimosegawa T. Exosomes Derived From Pancreatic Stellate Cells: MicroRNA Signature and Effects on Pancreatic Cancer Cells. *Pancreas* 2017; **46**: 19-27 [PMID: 27841793 DOI: 10.1097/MPA.0000000000000722]
 - 35 **Leca J**, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy C, Sergé A, Lavaut MN, Dusetti N, Loncle C, Roques J, Pietrasz D, Bousquet C, Garcia S, Granjeaud S, Ouassii M, Bachet JB, Brun C, Iovanna JL, Zimmermann P, Vasseur S, Tomasini R. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. *J Clin Invest* 2016; **126**: 4140-4156 [PMID: 27701147 DOI: 10.1172/JCI87734]
 - 36 **Patel GK**, Khan MA, Bhardwaj A, Srivastava SK, Zubair H, Patton MC, Singh S, Khushman M, Singh AP. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. *Br J Cancer* 2017; **116**: 609-619 [PMID: 28152544 DOI: 10.1038/bjc.2017.18]
 - 37 **Sherman MH**, Yu RT, Engle DD, Ding N, Atkins AR, Tiriach H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM. Vitamin D receptor-mediated stromal reprogramming suppresses

- pancreatitis and enhances pancreatic cancer therapy. *Cell* 2014; **159**: 80-93 [PMID: 25259922 DOI: 10.1016/j.cell.2014.08.007]
- 38 **Hah N**, Sherman MH, Yu RT, Downes M, Evans RM. Targeting Transcriptional and Epigenetic Reprogramming in Stromal Cells in Fibrosis and Cancer. *Cold Spring Harb Symp Quant Biol* 2015; **80**: 249-255 [PMID: 26801159 DOI: 10.1101/sqb.2015.80.027185]
- 39 **Sarper M**, Cortes E, Lieberthal TJ, Del Río Hernández A. ATRA modulates mechanical activation of TGF- β by pancreatic stellate cells. *Sci Rep* 2016; **6**: 27639 [PMID: 27375161 DOI: 10.1038/srep27639]
- 40 **Jaster R**, Hilgendorf I, Fitzner B, Brock P, Sparmann G, Emmrich J, Liebe S. Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. *Biochem Pharmacol* 2003; **66**: 633-641 [PMID: 12906928 DOI: 10.1016/S0006-2952(03)00390-3]
- 41 **McCarroll JA**, Phillips PA, Santucci N, Pirola RC, Wilson JS, Apte MV. Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis. *Gut* 2006; **55**: 79-89 [PMID: 16043492 DOI: 10.1136/gut.2005.064543]
- 42 **Froeling FE**, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt- β -catenin signaling to slow tumor progression. *Gastroenterology* 2011; **141**: 1486-1497, 1497.e1-1497.14 [PMID: 21704588 DOI: 10.1053/j.gastro.2011.06.047]
- 43 **Chronopoulos A**, Robinson B, Sarper M, Cortes E, Auernheimer V, Lachowski D, Attwood S, García R, Ghassemi S, Fabry B, Del Río Hernández A. ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion. *Nat Commun* 2016; **7**: 12630 [PMID: 27600527 DOI: 10.1038/ncomms12630]
- 44 **Kozono S**, Ohuchida K, Eguchi D, Ikenaga N, Fujiwara K, Cui L, Mizumoto K, Tanaka M. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. *Cancer Res* 2013; **73**: 2345-2356 [PMID: 23348422 DOI: 10.1158/0008-5472.CAN-12-3180]
- 45 **Suklabaidya S**, Das B, Ali SA, Jain S, Swaminathan S, Mohanty AK, Panda SK, Dash P, Chakraborty S, Batra SK, Senapati S. Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia. *Oncotarget* 2016; **7**: 41825-41842 [PMID: 27259232 DOI: 10.18632/oncotarget.9729]
- 46 **Hama K**, Ohnishi H, Aoki H, Kita H, Yamamoto H, Osawa H, Sato K, Tamada K, Mashima H, Yasuda H, Sugano K. Angiotensin II promotes the proliferation of activated pancreatic stellate cells by Smad7 induction through a protein kinase C pathway. *Biochem Biophys Res Commun* 2006; **340**: 742-750 [PMID: 16380081 DOI: 10.1016/j.bbrc.2005.12.069]
- 47 **Yamada T**, Kuno A, Masuda K, Ogawa K, Sogawa M, Nakamura S, Ando T, Sano H, Nakazawa T, Ohara H, Nomura T, Joh T, Itoh M. Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. *J Pharmacol Exp Ther* 2003; **307**: 17-23 [PMID: 12944495 DOI: 10.1124/jpet.103.053322]
- 48 **Masamune A**, Hamada S, Kikuta K, Takikawa T, Miura S, Nakano E, Shimosegawa T. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. *Scand J Gastroenterol* 2013; **48**: 602-609 [PMID: 23477656 DOI: 10.3109/00365521.2013.777776]
- 49 **Kadera BE**, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. *PLoS One* 2013; **8**: e71978 [PMID: 23991015 DOI: 10.1371/journal.pone.0071978]
- 50 **Donahue TR**, Nguyen AH, Moughan J, Li L, Tatishev S, Toste P, Farrell JJ. Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer. *J Surg Oncol* 2014; **110**: 952-959 [PMID: 25132574 DOI: 10.1002/jso.23750]
- 51 **Negoi I**, Hostiu S, Sartelli M, Negoi RI, Beuran M. MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer - A systematic review and meta-analysis. *Am J Surg* 2017; **214**: 515-524 [PMID: 28477839 DOI: 10.1016/j.amjsurg.2017.03.049]
- 52 **Frampton AE**, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, Jiao LR, Stebbing J. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. *Eur J Cancer* 2015; **51**: 1389-1404 [PMID: 26002251 DOI: 10.1016/j.ejca.2015.04.006]
- 53 **Xiong G**, Feng M, Yang G, Zheng S, Song X, Cao Z, You L, Zheng L, Hu Y, Zhang T, Zhao Y. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. *Cancer Lett* 2017; **397**: 94-102 [PMID: 28254409 DOI: 10.1016/j.canlet.2017.02.020]
- 54 **Bailey JM**, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA. Sonic hedgehog promotes desmoplasia in pancreatic cancer. *Clin Cancer Res* 2008; **14**: 5995-6004 [PMID: 18829478 DOI: 10.1158/1078-0432.CCR-08-0291]
- 55 **Olive KP**, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* 2009; **324**: 1457-1461 [PMID: 19460966 DOI: 10.1126/science.1171362]
- 56 **Stephenson J**, Richards DA, Wolpin BM, Becerra C, Hamm JT, Messersmith WA, Devens S, Cushing J, Goddard J, Schmalbach T, Fuchs CS. The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer. *J Clin Oncol* 2011; **29**: Abstract 4114 [DOI: 10.1200/jco.2011.29.15_suppl.4114]
- 57 **Ko AH**, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. *Pancreas* 2016; **45**: 370-375 [PMID: 26390428 DOI: 10.1097/MPA.0000000000000458]
- 58 **Catenacci DV**, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. *J Clin Oncol* 2015; **33**: 4284-4292 [PMID: 26527777 DOI: 10.1200/JCO.2015.62.8719]
- 59 **Mahlbacher V**, Sewing A, Elsässer HP, Kern HF. Hyaluronan is a secretory product of human pancreatic adenocarcinoma cells. *Eur J Cell Biol* 1992; **58**: 28-34 [PMID: 1644063]
- 60 **Jacobetz MA**, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kulti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. *Gut* 2013; **62**: 112-120 [PMID: 22466618 DOI: 10.1136/gutjnl-2012-302529]
- 61 **Theocharis AD**, Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. *Biochim Biophys Acta* 2000; **1502**: 201-206 [PMID: 11040445 DOI: 10.1016/S0925-4439(00)00051-X]
- 62 **Takada M**, Yamamoto M, Saitoh Y. The significance of CD44 in human pancreatic cancer: I. High expression of CD44 in human pancreatic adenocarcinoma. *Pancreas* 1994; **9**: 748-752 [PMID: 7531334 DOI: 10.1097/00006676-199411000-00014]
- 63 **Immervoll H**, Hoem D, Steffensen OJ, Miletic H, Molven A. Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. *J Histochem Cytochem* 2011; **59**: 441-455 [PMID: 21411814 DOI: 10.1369/002155411398275]
- 64 **Sato N**, Kohi S, Hirata K, Goggins M. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. *Cancer Sci* 2016; **107**: 569-575 [PMID: 26918382 DOI: 10.1111/cas.12913]
- 65 **Teranishi F**, Takahashi N, Gao N, Akamo Y, Takeyama H, Manabe T, Okamoto T. Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. *Cancer Sci* 2009; **100**: 770-777 [PMID: 19469020 DOI: 10.1111/j.1349-7006.2009.01084.x]

- 66 **Kulthi A**, Zhao C, Singha NC, Zimmerman S, Osgood RJ, Symons R, Jiang P, Li X, Thompson CB, Infante JR, Jacobetz MA, Tuveson DA, Frost GI, Shepard HM, Huang Z. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. *Biomed Res Int* 2014; **2014**: 817613 [PMID: 25147816 DOI: 10.1155/2014/817613]
- 67 **Cheng XB**, Kohi S, Koga A, Hirata K, Sato N. Hyaluronan stimulates pancreatic cancer cell motility. *Oncotarget* 2016; **7**: 4829-4840 [PMID: 26684359 DOI: 10.18632/oncotarget.6617]
- 68 **Shepard HM**. Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy. *Front Oncol* 2015; **5**: 192 [PMID: 26380222 DOI: 10.3389/fonc.2015.00192]
- 69 **Provenzano PP**, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. *Br J Cancer* 2013; **108**: 1-8 [PMID: 23299539 DOI: 10.1038/bjc.2012.569]
- 70 **Wong KM**, Horton KJ, Coveler AL, Hingorani SR, Harris WP. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). *Curr Oncol Rep* 2017; **19**: 47 [PMID: 28589527 DOI: 10.1007/s11912-017-0608-3]
- 71 **Provenzano PP**, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. *Cancer Cell* 2012; **21**: 418-429 [PMID: 22439937 DOI: 10.1016/j.ccr.2012.01.007]
- 72 **Hingorani SR**, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard HM, Devoe CE. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. *Clin Cancer Res* 2016; **22**: 2848-2854 [PMID: 26813359 DOI: 10.1158/1078-0432.CCR-15-2010]
- 73 **Hingorani SR**, Bullock AJ, Seery TE, Zheng L, Sigal D, Ritch PS. Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA). *J Clin Oncol* 2017; **15**: Abstract 4008
- 74 **Ramanathan RK**, McDonough S, Philip PA, et al. A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). Oral presentation at: 2018 Gastrointestinal Cancers Symposium; January 18-20, 2018; San Francisco, CA.
- 75 **Guweidhi A**, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T, Büchler MW, Berger MR, Friess H. Osteonectin influences growth and invasion of pancreatic cancer cells. *Ann Surg* 2005; **242**: 224-234 [PMID: 16041213 DOI: 10.1097/01.sla.0000171866.45848.68]
- 76 **Neuzillet C**, Tijeras-Raballand A, Cros J, Faivre S, Hammel P, Raymond E. Stromal expression of SPARC in pancreatic adenocarcinoma. *Cancer Metastasis Rev* 2013; **32**: 585-602 [PMID: 23690170 DOI: 10.1007/s10555-013-9439-3]
- 77 **Vaz J**, Ansari D, Sasor A, Andersson R. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer. *Pancreas* 2015; **44**: 1024-1035 [PMID: 26335014 DOI: 10.1097/MPA.0000000000000409]
- 78 **Rossi MK**, Gnanamony M, Gondi CS. The 'SPARC' of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review). *Int J Oncol* 2016; **48**: 1765-1771 [PMID: 26983777 DOI: 10.3892/ijo.2016.3417]
- 79 **Ting DT**, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW, Xega K, Ciciliano JC, Zhu H, MacKenzie OC, Trautwein J, Arora KS, Shahid M, Ellis HL, Qu N, Bardeesy N, Rivera MN, Deshpande V, Ferrone CR, Kapur R, Ramaswamy S, Shioda T, Toner M, Maheswaran S, Haber DA. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. *Cell Rep* 2014; **8**: 1905-1918 [PMID: 25242334 DOI: 10.1016/j.celrep.2014.08.029]
- 80 **Mantoni TS**, Schendel RR, Rödel F, Niedobitek G, Al-Assar O, Masamune A, Brunner TB. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. *Cancer Biol Ther* 2008; **7**: 1806-1815 [PMID: 18787407 DOI: 10.4161/cbt.7.11.6846]
- 81 **Koshiba T**, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee JU, Doi R, Arai S, Imamura M. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. *Cancer* 1998; **82**: 642-650 [PMID: 9477095 DOI: 10.1002/(SICI)1097-0142(19980215)82:43.0.CO;2-N]
- 82 **Bloomston M**, Zervos EE, Rosemurgy AS 2nd. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. *Ann Surg Oncol* 2002; **9**: 668-674 [PMID: 12167581 DOI: 10.1007/BF02574483]
- 83 **Gundewar C**, Sasor A, Hilmersson KS, Andersson R, Ansari D. The role of SPARC expression in pancreatic cancer progression and patient survival. *Scand J Gastroenterol* 2015; **50**: 1170-1174 [PMID: 25765175 DOI: 10.3109/00365521.2015.1024281]
- 84 **Infante JR**, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, Goggins M. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. *J Clin Oncol* 2007; **25**: 319-325 [PMID: 17235047 DOI: 10.1200/JCO.2006.07.8824]
- 85 **Han W**, Cao F, Chen MB, Lu RZ, Wang HB, Yu M, Shi CT, Ding HZ. Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. *PLoS One* 2016; **11**: e0145803 [PMID: 26731428 DOI: 10.1371/journal.pone.0145803]
- 86 **Von Hoff DD**, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase III trial. *J Clin Oncol* 2011; **29**: 4548-4554 [PMID: 21969517 DOI: 10.1200/JCO.2011.36.5742]
- 87 **Von Hoff DD**, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; **369**: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]

P- Reviewer: Matsuda Y, Negoi I, Ramasamy TS **S- Editor:** Ji FF
L- Editor: A **E- Editor:** Tan WW





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

